Consensus estimates for Q2 2026 place revenue at $63.46 million with an expected adjusted loss of $0.03 per share, while the stock currently trades near $4.20 against a $6.60 average analyst price target.
Investors are primarily focused on the recovery trajectory of the Wound Care segment following a massive 60% revenue plunge in the first quarter caused by new Medicare reimbursement caps. This disruption led management to slash full-year 2026 guidance and initiate a 15% workforce reduction in April to preserve capital. Analysts are now looking for signs that volume in wound care centers has stabilized and that the company’s surgical business can maintain its double-digit growth to offset broader market volatility.